je.st
news
Tag: liver
Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-8742) at the 65th American Association for the Study of Liver Diseases Annual Meeting
2014-10-08 17:13:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Interim results of C-SWIFT, a Phase 2 study evaluating ultra-short treatment durations of grazoprevir/elbasvir (MK-5172/MK-8742) plus sofosbuvir, to be presented Results from the C-WORTHy study, a Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742) across multiple patient populations, including difficult-to-cure, to be presented WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data from clinical studies of the companys investigational, oral, once-daily, fixed-dose combination chronic hepatitis C treatment grazoprevir/elbasvir (MK-5172/MK-8742) are scheduled to be presented at the 65th American Association for the Study of Liver Diseases (AASLD) Annual Meeting, also known as The Liver Meeting. The meeting is scheduled to take place at the John B. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
data
present
american
International Scientific Forum on Alcohol Research Critique 148: Alcohol and Liver Cancer
2014-09-24 13:41:00| Daily beverage news and comment - from just-drinks.com
Hepatic cirrhosis frequently precedes the development of liver cancer, and excessive alcohol consumption is known to be one cause of cirrhosis.
Tags: forum
international
research
scientific
InterMune drug may offer big upside to Roche if aimed at liver
2014-08-28 06:40:43| Biotech - Topix.net
Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its buck.
Eli Lilly drug comes up short in liver cancer trial
2014-06-12 05:54:54| Agriculture - Topix.net
A study on patients with advanced liver cancer using Eli Lilly and Co.' s new cancer drug Cyramza failed to meet its primary goal of overall patient survival.
Merck to Present New Data for Investigational Hepatitis C Treatments MK-5172 and MK-8742 at EASL Annual Meeting/The International Liver Congress 2014
2014-03-24 12:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Company to Initiate Phase 3 Clinical Development Program in Q2 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new Phase 2 data for its two investigational hepatitis C virus (HCV) treatments - MK-5172, an investigational HCV NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor are scheduled to be presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), also known as The International Liver Congress 2014. Language: English Contact: MerckMedia Contacts:Caroline Lappetito, 267-305-7639Sarra Herzog, 908-423-6154orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
international
present
annual
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] next »